OptiBiotix Health PLC Grant of Options (7869U)
17 July 2018 - 4:00PM
UK Regulatory
TIDMOPTI
RNS Number : 7869U
OptiBiotix Health PLC
17 July 2018
OPTIBIOTIX HEALTH PLC (the "Company")
Grant of Options
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces the Company's Remuneration Committee has
proposed a grant of options under the Company's approved EMI Scheme
("the Scheme"), to certain directors and employees.
Director Number of options Exercise price
Neil Davidson 385,000 73p
------------------ ---------------
Sofia Kolyda 165,000 73p
------------------ ---------------
Others 165,000 73p
------------------ ---------------
Under the rules of the Scheme the participants have up to 30
days from the date of offer, 13 July 2018, to complete the
requisite documentation after which the Options will automatically
lapse. Once the documentation has been received by the Company and
approved by the board the option grant will become effective ("the
Effective Date"). The options may be exercised up to 10 years from
the Effective Date.
The options have performance criteria attached to them which
includes a doubling in the share price and significant revenue
targets. Option holders can only purchase and/or sell shares once
these conditions have been met. This ensures a continued focus on
commercial revenues and shareholder value creation.
A further announcement will be made confirming the Effective
Date.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 and the person who arranged
for release of this announcement on behalf of the Company was
Stephen O'Hara, Chief Executive.
Stephen O'Hara, CEO of OptiBiotix, commented: "The ability to
attract and retain key staff who deliver to performance targets
which build shareholder value is important to OptiBiotix' continued
success. The granting of share options helps OptiBiotix compete
with the remuneration packages offered by larger corporates and
incentivises the team to focus both effort and activity on rapidly
growing revenues and building shareholder value. These options are
offered to staff do not become exercisable (i.e. sellable) until
they achieve significant performance targets which if achieved will
create substantive shareholder value".
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Cairn Financial Advisers LLP Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Abigail Wayne (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHSFAFLMFASEFW
(END) Dow Jones Newswires
July 17, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024